Key Takeaways
- • Companies across North Carolina's Research Triangle raised $99 million in Q3 2026, a steep decline from the region's average of $498 million per quarter across 37 deals over the past few years, according to PitchBook and NVCA's latest Venture Monitor.
- • Only 29 funding rounds were reported in Q3 2026, and just four were above $5 million, pointing to a market dominated by small deals.
- • Biotech and health companies made up about half of the top 20 deals in the Durham and Raleigh MSAs, and many of the smaller rounds appear to be bridge financings ahead of larger raises expected in late 2026 and 2027.
- • Investors cite a tight funding environment shaped by a lack of exits, limited LP distributions, and higher interest rates that make fund formation harder.
- • Federal funding uncertainty, including DOGE cuts and NIH unpredictability, is pushing regional biotech companies such as Dignify Therapeutics toward private capital.
Summary
Companies across North Carolina's Research Triangle raised $99 million in the third quarter of 2026, a steep drop from the region's historical average. Over the past several years, Triangle startups have averaged a quarterly total of $498 million across 37 deals. In Q3 2026, the region recorded just 29 funding rounds, only four of which exceeded $5 million, according to the latest Venture Monitor report from PitchBook and the National Venture Capital Association.
Jason Caplain, cofounder of software-focused investment firm Bull City Venture Partners, said the decline is not overly concerning, noting that investment totals in the Raleigh, Durham and Chapel Hill area have historically been volatile. "The numbers in North Carolina tend to be very, very lumpy," Caplain told Technical.ly. Nationally, funding is also concentrating in fewer companies. The median Series D deal in the US this year has been $150 million, up from $100 million last year, and the DC region, Baltimore and Pittsburgh are seeing similar concentration.
About half of the top 20 deals in the Durham and Raleigh MSAs were in biotech and health, consistent with the region's industry mix. Notably, many were small. Mike Carnes, emerging company development VP at the NC Biotechnology Center, said deals of a few million dollars or less suggest that bridge rounds are common, with startups raising capital to reach key milestones before larger financings. He said significant financings could occur in the fourth quarter or early 2027. Carnes also noted that some larger Q3 deals may not yet appear in PitchBook data, citing Slate Medicines' ongoing effort to raise $245 million alongside its merger with Fulcrum Therapeutics.
Dignify Therapeutics of Durham is an example of this pattern. The company raised $800,000 in the quarter from a founder and a founding investor to fund operations and investor outreach ahead of a planned $75 million raise, according to Executive Chairman Tony Ditonno. He expects to close $25 million by the first quarter of 2027 and the remaining $50 million by the end of 2028. The company is developing two drugs for people with spinal cord injuries seeking greater control over bowel and bladder function and has received about $20 million in non-dilutive National Institutes of Health funding. Ditonno said reliance on federal money has become less dependable since the Trump administration's DOGE cuts and NIH funding unpredictability, and that competition for capital is intensifying. The company recently received FDA clearance for one drug, which investors are seeking as evidence of progress in human trials.
Caplain said the broader market is difficult, citing a shortage of exits that limits cash returned to limited partners and makes fundraising harder amid higher interest rates. He said venture firms are having to hold portfolio companies longer due to scarce capital, and that founders are most successful when introduced through warm referrals rather than cold outreach.
Jason Caplain, cofounder of software-focused investment firm Bull City Venture Partners, said the decline is not overly concerning, noting that investment totals in the Raleigh, Durham and Chapel Hill area have historically been volatile. "The numbers in North Carolina tend to be very, very lumpy," Caplain told Technical.ly. Nationally, funding is also concentrating in fewer companies. The median Series D deal in the US this year has been $150 million, up from $100 million last year, and the DC region, Baltimore and Pittsburgh are seeing similar concentration.
About half of the top 20 deals in the Durham and Raleigh MSAs were in biotech and health, consistent with the region's industry mix. Notably, many were small. Mike Carnes, emerging company development VP at the NC Biotechnology Center, said deals of a few million dollars or less suggest that bridge rounds are common, with startups raising capital to reach key milestones before larger financings. He said significant financings could occur in the fourth quarter or early 2027. Carnes also noted that some larger Q3 deals may not yet appear in PitchBook data, citing Slate Medicines' ongoing effort to raise $245 million alongside its merger with Fulcrum Therapeutics.
Dignify Therapeutics of Durham is an example of this pattern. The company raised $800,000 in the quarter from a founder and a founding investor to fund operations and investor outreach ahead of a planned $75 million raise, according to Executive Chairman Tony Ditonno. He expects to close $25 million by the first quarter of 2027 and the remaining $50 million by the end of 2028. The company is developing two drugs for people with spinal cord injuries seeking greater control over bowel and bladder function and has received about $20 million in non-dilutive National Institutes of Health funding. Ditonno said reliance on federal money has become less dependable since the Trump administration's DOGE cuts and NIH funding unpredictability, and that competition for capital is intensifying. The company recently received FDA clearance for one drug, which investors are seeking as evidence of progress in human trials.
Caplain said the broader market is difficult, citing a shortage of exits that limits cash returned to limited partners and makes fundraising harder amid higher interest rates. He said venture firms are having to hold portfolio companies longer due to scarce capital, and that founders are most successful when introduced through warm referrals rather than cold outreach.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.